Drugmaker signs agreement to support INDOX cancer research centres in India
French drugmaker Sanofi-aventis and Oxford University have entered into an agreement with INDOX to conduct multi-phase oncology clinical and translational research in India.
INDOX is a partnership between Oxford University and India's top eight cancer research centres.
Sanofi-aventis said that through this partnership, the company will have access to the expertise and experience of India's top oncologists and scientists, which will help it to conduct clinical research.
Under the terms of the agreement, sanofi-aventis will provide financial support to Oxford University to manage the INDOX network. The University, on its part, will provide training and support to investigators and research coordinators to help ensure that each centre has the capacity, expertise and infrastructure to perform early- through late-stage and post-marketing clinical trials according to ICH/GCP standards.
‘The collaboration between sanofi-aventis, Oxford University and the Indian Cancer Centres fosters a model for academic researchers and industry to work together for the benefit of patients,’ said Debasish Roychowdhury, senior vice president, head of oncology at sanofi-aventis.
‘This relationship not only helps to train the next generation of cancer researchers in India, but also allows sanofi-aventis to efficiently develop drugs in the premier cancer centres in India, which also provides access to anticancer drugs to help patients fight their cancer.’